Two Cases of Possible Exacerbation of Chronic Rejection After Anti-SARS-CoV-2 Messenger RNA Vaccination: A Case Report

3Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Your institution provides access to this article.

Abstract

In post–liver transplant recipients, SARS-CoV-2 infection is a health threat, and novel messenger RNA vaccines such as Pfizer BioNTech BNT162b2 and Moderna mRNA-1273 are aggressively recommended. However, there are few reports on their adverse effects, some of which may be potentially fatal. We have experienced 2 post–liver transplant recipients with exacerbated chronic rejection after vaccination, one of whom had to undergo retransplant and the other who is still in the process of liver function without improvement. These alarming cases will be presented as case reports.

Cite

CITATION STYLE

APA

Okamoto, T., Okajima, H., Ogawa, E., Uebayashi, E. Y., Yamamoto, M., Kadohisa, M., … Hatano, E. (2023). Two Cases of Possible Exacerbation of Chronic Rejection After Anti-SARS-CoV-2 Messenger RNA Vaccination: A Case Report. Transplantation Proceedings, 55(3), 530–532. https://doi.org/10.1016/j.transproceed.2022.11.009

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free